5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller

2. Insmed (NASDAQ:INSM)

Druckenmiller’s Stake: $188,717,000

Insmed (NASDAQ:INSM) makes treatments for serious lung diseases caused by chronic inflammation or infection. Its core products are Brinsupri (brensocatib) and Arikayce.

In 2025, Brinsupri generated about $144.6 million in Q4 sales, bringing full-year revenue to roughly $600+ million, reflecting very strong early launch growth. This represents around 67% year-over-year growth. For 2026, Insmed expects Brinsupri to hit about $1 billion in annual sales, driven by broader patient adoption.

Arikayce in 2025 generated about $433.8 million in full-year sales, up 19% year over year, and the company guided 2026 sales of $450–$470 million.

Insmed’s (NASDAQ:INSM) pipeline is also strong. One key candidate is TPIP (treprostinil inhalation powder), a treatment being developed for PAH (pulmonary arterial hypertension) and PH-ILD (pulmonary hypertension associated with interstitial lung disease). Some estimates suggest the product can potentially generate over $4 billion in peak annual sales.

Artisan Small Cap Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its fourth quarter 2025 investor letter:

“Our top contributors in Q4 were MACOM Technology Solutions, Insmed Incorporated (NASDAQ:INSM) and Vita Coco. Insmed is a biotechnology company focused on pulmonary diseases. We exited our position during the quarter due to market cap considerations, though the stock remained a top performer. Its strength was driven by the successful launch of Brinsupri™ (brensocatib), the first approved therapy for non-cystic fibrosis bronchiectasis, which generated $28 million in initial sales from roughly 2,500 patients and 1,700 prescribers, along with a robust pipeline of additional potential therapies.”